Of 765 patients with disseminated metastatic carcinoma of the colon and rectum treated at Memorial Sloan-Kettering Cancer Center during the ten-year period 1960--1970, 53 (6.9 per cent) had skeletal metastases. Of these, 14 (1.8 per cent) had osseous metastases only. In one case the osseous lesion was the first symptom of a cancer of the sigmoid colon, and one patient had metastasis in the fibula from a primary rectal cancer. In our series the incidences of osseous metastases were 8.9 per cent from rectal carcinoma and 5.1 per cent from colonic carcinoma. The mean period from manifestation of skeletal metastasis to death was 13.2 months.

No abstract

This is a report of 138 male patients with cancer of the breast who were treated at the Hellenic Anticancer Institute from 1937 to 1974. The overall 5-year survival rate for 120 patients followed up was 32.5%. Analysis of the 5-year survival rate in relation to the mode of treatment showed that for radical mastectomy it was 42.9%, for simple mastectomy 40.7%, and for lumpectomy 35%. There were no 5-year survivors among patients treated with a combination of radiotherapy, chemotherapy, and hormonal manipulation. The 5-year survival rate for stage I cancer was 54.6%, for stage II the rate was 48.7%, and for stage III it was 18.5%. There were no 5-year survivors with stage IV cancer. The 5-year survival rate for patients who underwent radical mastectomy with positive axillary lymph nodes was 30.8%, while for those in whom the axillary lymph nodes were negative it was 56.5%. The overall 10-year survival rate was 14.8%.

There was no difference in efficacy between the two combinations. Toxicity was greater with the LV + 5-FU + IFN-alpha regimen because of the flu-like syndrome.

Sera from patients with nasopharyngeal carcinoma (NPC) or other malignant diseases and from apparently healthy controls were examined for Epstein-Barr virus (EBV) antibodies. A difference existed in the percentage of positive sera among the groups studied. High-titer antibody levels were observed in the NPC group, but no statistical difference was found among other groups of patients and controls. The data reaffirmed the association of EBV with NPC but did not support its etiologic role in the development of other human neoplasms.